Eptacog Alfa Market

Recombinant human coagulation factor VIIa is a drug from Novo Nordisk for bleeding episodes and prevention of bleeding during surgical procedures or invasive procedures in the following patient groups:
1. Inhibitors of coagulation factor VIII or IX 5BU in congenital hemophilia patients; 2. Congenital hemophilia patients who are expected to have a high memory response to injection of coagulation factor VIII or coagulation factor IX; 3. Acquired blood 4. Patients with congenital FVII deficiency; 5. Patients with thrombocytopenia who have GP IIb-IIIa and/or HLA antibodies and past or present ineffective or poor platelet transfusions.
Eptacog Alfa Market contains market size and forecasts of Eptacog Alfa (rFVIIa) in global, including the following market information:
Global Eptacog Alfa (rFVIIa) Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Eptacog Alfa (rFVIIa) Market Sales, 2017-2022, 2023-2028, (g)
Global top five Eptacog Alfa (rFVIIa) companies in 2021 (%)
The global Eptacog Alfa (rFVIIa) market was valued at 1224.5 million in 2021 and is projected to reach US$ 1655.4 million by 2028, at a CAGR of 4.4% during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Freeze-dried Preparation Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Eptacog Alfa (rFVIIa) include Novo Nordisk, LFB SA, GENERIUM, Northland-bio, CSL, Shire (Takeda) and Bayer, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Eptacog Alfa (rFVIIa) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Eptacog Alfa (rFVIIa) Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (g)
Global Eptacog Alfa (rFVIIa) Market Segment Percentages, by Type, 2021 (%)
Freeze-dried Preparation
Freeze-dried Powder
Global Eptacog Alfa (rFVIIa) Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (g)
Global Eptacog Alfa (rFVIIa) Market Segment Percentages, by Application, 2021 (%)
Hemophilia
Acquired Hemophilia
Factor VII Deficiency
Glanzmann Thrombasthenia (GT)
Global Eptacog Alfa (rFVIIa) Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (g)
Global Eptacog Alfa (rFVIIa) Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Eptacog Alfa (rFVIIa) revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Eptacog Alfa (rFVIIa) revenues share in global market, 2021 (%)
Key companies Eptacog Alfa (rFVIIa) sales in global market, 2017-2022 (Estimated), (g)
Key companies Eptacog Alfa (rFVIIa) sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novo Nordisk
LFB SA
GENERIUM
Northland-bio
CSL
Shire (Takeda)
Bayer